Amarantus Bioscience Holdings Inc (AMBS)

[rand0m]

AMBS mentioned in Seeking Alpha Article (big boards)!!

Seems like the news says the company hasn't sold any shares since the 10Q got released. I've been waiting quiet to get in again today.

Been playing ACAD (big board) and saw a seeking alpha article mentioning AMBS. Don't see seeking alpha posting stuff abt penny stocks that much but when it does, it does generate buzzzzZZZ

http://seekingalpha.com/article/1042461-acadia-hits-home-run-in-phase-3-trial-and-brings-market-focus-to-parkinson-s?source=yahoo

About AMBS:

Amarantus Bioscience (AMBS.OB)is a development-stage biotechnology company founded in January 2008. The company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.

The potential of MANF technology has been recognized by some of the biggest names in the biotech space. Just last month, the company announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. "I believe in MANF," said Dr. Rubinfeld. "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen... I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the company's new orphan drug strategy could get MANF to market rather expeditiously." Dr. Rubinfeld went on to add that MANF has the commercial potential to become a blockbuster drug.

About Parkinson's disease:

Parkinson's disease psychosis is a debilitating disorder that develops in up to 60% of patients with Parkinson's disease. Currently, there is no FDA-approved therapy to treat PDP in the United States.